Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 293-321 , October 2002

Positron emission tomography imaging in nonmalignant thoracic disorders

  • Abass Alavi

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
    • Corresponding Author InformationAddress reprint requests to Abass Alavi, Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104
    • ,
  • Naresh Gupta

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
    • ,
  • Jean-Louis Alberini

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
    • ,
  • Marc Hickeson

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
    • ,
  • Lars-Eric Adam

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
    • ,
  • Peeyush Bhargava

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
    • ,
  • Hongming Zhuang

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA

References 

  1. Cook G, Fogelman I, Maisey M. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. In: Semin Nucl Med. 26:1996;p. 308–314
  2. Engel H, Steinert H, Buck A, et al. Whole-body PET: Physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med. 1996;37:441–446
  3. Bakheet S, Powe J. 18-FDG uptake due to benign pathology. In: Semin Nucl Med. 28:1998;p. 352–358
  4. Cook G, Maisey M, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363–1378
  5. Strauss L. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409–1415
  6. Shreve P, Anzai Y, Wahl R. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics. 1999;19:61–77
  7. Wahl R. To AC or not to AC: That is the question. J Nucl Med. 1999;40:2025–2028
  8. Zasadny K, Kison P, Quint L, et al. Untreated lung cancer: Quantification of systematic distortion of tumor size and shape on non-attenuation corrected 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET scans. Radiology. 1996;201:873–876
  9. Bengel F, Ziegler S, Avril N. Whole-body positron emission tomography in clinical oncology: Comparison between attenuation corrected and uncorrected images. Eur J Nucl Med. 1997;24:1091–1098
  10. Imran M, Kubota K, Yamada S, et al. Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images. J Nucl Med. 1998;39:1219–1223
  11. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: The role of statistical reconstruction. Eur J Nucl Med. 1999;26:591–598
  12. Kotzerke J, Guhlmann A, Moog F, et al. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med. 1999;26:31–38
  13. Bleckmann C, Dose J, Bohuslavizki K, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med. 1999;40:2021–2024
  14. Hustinx R, Dolin R, Benard F, et al. Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: A free-response ROC analysis. Eur J Nucl Med. 2000;27:1365–1371
  15. Chan W, Freund J, Pocock N, et al. Coincidence detection FDG PET in the management of oncological patients: Attenuation correction versus non-attenuation correction. Nucl Med Commun. 2001;22:1185–1192
  16. Bedigian M, Benard F, Smith R, et al. Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. Eur J Nucl Med. 1998;25:659–661
  17. Carson R, Daube-Witherspoon M, Green M. A method for postinjection PET transmission measurements with a rotating source. J Nucl Med. 1988;29:1558–1567
  18. Karp J, Muehllehner G, Qu H, et al. Singles transmission in volume-imaging PET with a 137Cs source. Phys Med Biol. 1995;40:929–944
  19. Smith R, Karp J. Singles transmission scans performed postinjection for quantitative whole body PET imaging. IEEE Trans Nucl Sci. 1997;44:1329–1335
  20. Meikle S, Eberl S, Hooper P, et al. Simultaneous emission and transmission (SET) scanning in neurological PET studies. J Comput Assist Tomogr. 1997;21:487–497
  21. Hudson H, Larkin R. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imag. 1994;13:601–609
  22. Riddell C, Carson R, Carrasquillo J, et al. Noise reduction in oncology FDG PET images by iterative reconstruction: A quantitative assessment. J Nucl Med. 2001;42:1316–1323
  23. Benard F, Smith R, Hustinx R, et al. Clinical evaluation of processing techniques for attenuation correction with 137Cs in whole body PET imaging. J Nucl Med. 1999;40:1257–1263
  24. Paul A, Tatsumi M, Yutani K, et al. Effects of iterative reconstruction on image contrast and lesion detection in gamma camera coincidence imaging in lung and breast cancers. Nucl Med Commun. 2002;23:103–110
  25. Choi Y, Brunken R, Hawkins R, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-d-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med. 1993;20:308–318
  26. (abstr) Duarte P, Saghari H, Zhuang HM, et al. The association between chronic obstructive pulmonary disease and right ventricle uptake in whole body PET scans. In: 2001 Annual Meeting of the Academy of Molecular Imaging. Orlando, FL. Oct 24–27, 2001;
  27. Yun M, Yeh D, Araujo L, et al. F-18 FDG uptake in the large arteries: A new observation. Clin Nucl Med. 2001;26:314–319
  28. Yun M, Jang S, Cucchiara A, et al. 18F FDG uptake in the large arteries: A correlation study with the atherogenic risk factors. In: Semin Nucl Med. 32:2002;p. 70–76
  29. Lederman R, Raylman R, Fisher S, et al. Detection of atherosclerosis using novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun. 2001;22:747–753
  30. Zhang Z, Machac J, Helft G, et al. Noninvasive serial monitoring of atherosclerotic progression and regression with FDG-PET in a rabbit model. J Nucl Med. 2000;41:7P
  31. Lin E, Quaife R. FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging. Clin Nucl Med. 2001;26:241–242
  32. Bakheet S, Amin T, Alia A, et al. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med. 1999;24:995–997
  33. Patel P, Alibazoglu H, Ali A, et al. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med. 1996;21:772–775
  34. Brink I, Reinhardt M, Hoegerle S, et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: Age dependency and frequency after chemotherapy. J Nucl Med. 2001;42:591–595
  35. Alibazoglu H, Alibazoglu B, Hollinger E, et al. Normal thymic uptake of 2-deoxy-2[F-18]fluoro-d-glucose. Clin Nucl Med. 1999;24:597–600
  36. Rini J, Leonidas J, Tomas M, et al. 18F-FDG Uptake in the anterior mediastinum. Physiologic thymic uptake or disease?. Clin Positron Imaging. 2000;3:115–125
  37. Barrington S, Maisey M. Skeletal muscle uptake of fluorine-18-FDG: Effect of oral diazepam. J Nucl Med. 1996;37:1127–1129
  38. Minn H, Nuutila P, Lindholm P, et al. In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer. 1994;73:1490–1498
  39. Lin E, Bhola R. Unilateral diaphragmatic crus uptake on FDG positron emission tomographic imaging. Clin Nucl Med. 2001;26:479
  40. (abstr) Hickeson M, Kahn J, Zhuang H, et al. Demonstration of excessive metabolic activity of thoracic and abdominal muscles on FDG-PET in patients with COPD. J Nucl Med. 2002;43:1410S
  41. Yao W, Hoh C, Hawkins R, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794–799
  42. Hollinger E, Alibazoglu H, Ali A, et al. Hematopoietic cytokinemediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93–98
  43. Sugawara Y, Fisher S, Zasadny K, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173–180
  44. von Schulthess G, Meier N, Stumpe K. Joint accumulations of FDG in whole body PET scans. Nuklearmedizin. 2001;40:193–197
  45. Meyer M, Gast T, Raja S, et al. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med. 1994;19:13–14
  46. Cook G, Maisey M, Fogelman I. Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med. 1997;38:1495–1497
  47. Grigolon M, Delbeke D. F-18 FDG uptake in a bone infarct: A case report. Clin Nucl Med. 2001;26:613–614
  48. Sanchez Salmon A, Nunez R, Yeung H, et al. FGD PET in a patient with pseudofractures from osteomalacia. Rev Esp Med Nucl. 2002;21:34–35
  49. Alibazoglu H, Megremis D, Ali A, et al. Injection artifact on FDG PET imaging. Clin Nucl Med. 1998;23:264–265
  50. Kim W, Yun M, Alnafisi N, et al. False-negative interpretation of FDG positron emission tomography in a patient with Hodgkin's lymphoma. Clin Nucl Med. 2002;27:367–368
  51. Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055–1063
  52. Lin P, Delaney G, Chu J, et al. Fluorine-18 FDG dual-head gamma camera coincidence imaging of radiation pneumonitis. Clin Nucl Med. 2000;25:866–869
  53. Higashi K, Clavo A, Wahl R. In vitro assessment of 2-fluoro-2-deoxy-d-glucose, l-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med. 1993;34:773–779
  54. Fujibayashi Y, Waki A, Sakahara H, et al. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: From gene expression to deoxyglucose uptake. Radiat Res. 1997;147:729–734
  55. Daemen B, Elsinga P, Paans A, et al. Radiation-induced inhibition of tumor growth as monitored by PET using l-[1-11C]tyrosine and fluorine-18-fluorodeoxyglucose. J Nucl Med. 1992;33:373–379
  56. Hautzel H, Muller-Gartner H. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med. 1997;38:1384–1386
  57. Haberkorn U, Strauss L, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991;32:1485–1490
  58. Meyer M, Nathan C. Reduced F-18 fluorodeoxyglucose uptake within marrow after external beam radiation. Clin Nucl Med. 2000;25:279–280
  59. Higashi T, Fisher S, Brown R, et al. Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: Preclinical PET studies. J Nucl Med. 2000;41:2026–2035
  60. Ballinger J. Local and distant effects of radiotherapy on FDG accumulation in bone marrow. J Nucl Med. 2000;41:2036–2037
  61. Cummings SR, Lillington GA, Richard RJ. Estimating the probability of malignancy in solitary pulmonary nodules. A Bayesian approach. Am Rev Respir Dis. 1986;134:449–452
  62. Webb WR. Radiologic evaluation of the solitary pulmonary nodule. Am J Roentgenol. 1990;154:701–708
  63. Leef JL, Klein JS. The solitary pulmonary nodule. Radiol Clin North Am. 2002;40:123–143
  64. Dewan NA, Shehan CJ, Reeb SD, et al. Likelihood of malignancy in a solitary pulmonary nodule — Comparison of Bayesian analysis and results of FDG-PET scan. Chest. 1997;112:416–422
  65. Chechani V. Bronchoscopic diagnosis of solitary pulmonary nodules and lung masses in the absence of endobronchial abnormality. Chest. 1996;109:620–625
  66. Lacasse Y, Wong E, Guyatt GH, et al. Transthoracic needle aspiration biospy for the diagnosis of localised pulmonary lesions: A meta-analysis. Thorax. 1999;54:884–893
  67. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: A prospective study. J Nucl Med. 1990;31:1927–1933
  68. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: Detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology. 1992;184:441–444
  69. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary-abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487–490
  70. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: Potential role in evaluation and management. Chest. 1993;104:997–1002
  71. Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET: Comparison of findings in patients with and without a history of prior malignancy. Chest. 1996;109:982–988
  72. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J. 1996;9:410–414
  73. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16:1075–1084
  74. Prauer HW, Weber WA, Romer W, et al. Controlled prospective study of positron emission tomography using the glucose analogue F-18 fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg. 1998;85:1506–1511
  75. Duhaylongsod FG, Lowe VJ, Patz EF, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995;110:130–140
  76. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PET images. Clin Nucl Med. 1996;21:941–949
  77. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. In: Semin Nucl Med. 30:2000;p. 150–185
  78. Torizuka T, Zasadny KR, Recker B, et al. Untreated primary lung and breast cancers: Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology. 1998;207:767–774
  79. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39:1016–1020
  80. Kim BT, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. Am J Roentgenol. 1998;170:935–939
  81. (abstr) Zhuang H, Lee JH, Pourdehnad M, et al. In vitro investigation of FDG uptake in human inflammatory cells. J Nucl Med. 1999;40:888
  82. (abstr) Gupta NC, Bishop HA, Graeber GM. Incidence and characteristics of falsely positive and negative lymph nodes on PET and CT in lung cancer staging. J Nucl Med. 1999;40:229
  83. Hubner KF, Buonocore E, Singh SK, et al. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med. 1995;20:293–298
  84. Yen RF, Chen ML, Liu FY, et al. False-positive 2-F-18-fluoro-2-deoxy-d-glucose positron emission tomography studies for evaluation of focal pulmonary abnormalities. J Formos Med Assoc. 1998;97:642–645
  85. Zhuang H, Pourdehnad M, Yamamoto AJ, et al. Intense F-18 fluorodeoxyglucose uptake caused by Mycobacterium avium intracellulare infection. Clin Nucl Med. 2001;26:458
  86. Jones HA, Sriskandan S, Peters AM, et al. Dissociation of neutrophile migration and metabolic activity in lobar pneumonia and bronchiectasis. Eur Respir J. 1997;10:795–803
  87. Kapucu L, Meltzer C, Townsend D, et al. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med. 1998;39:1267–1269
  88. Bakheet S, Powe J, Ezzat A, et al. F-18-FDG uptake in tuberculosis. Clin Nucl Med. 1998;23:739–742
  89. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases. Radiology. 2000;216:117–121
  90. Hoekstra CJ, Hoekstra OS, Teengs JP, et al. Thoracic actinomycosis imaging with fluorine-18 fluorodeoxyglucose positron, emission tomography. Clin Nucl Med. 1999;24:529–530
  91. Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood. 1998;92:2719–2724
  92. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?. J Nucl Med. 1994;35:1650–1652
  93. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–1649
  94. Brudin LH, Valind SO, Rhodes CG, et al. F-18 Deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21:297–305
  95. Yasuda S, Shohtsu A, Ide M, et al. High fluorine-18 labeled deoxyglucose uptake in sarcoidosis. Clin Nucl Med. 1996;21:983–984
  96. Kiatboonsri C, Resnick SC, Chan KM, et al. The detection of recurrent sarcoidosis by FDG-PET in a lung transplant recipient. West J Med. 1998;168:130–132
  97. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160–1166
  98. (abstr) Oriuchi N, Inoue T, Tomiyoshi K, et al. F-18-Fluoro-alpha-methyl-tyrosine (FMT) and F-18-fluorodeoxyglucose (FDG) PET in patients with sarcoidosis. J Nucl Med. 1999;40:878
  99. (abstr) Zhuang HM, Yamamoto AJ, Pourdehnad M, et al. Detection of sarcoidosis by FDG-PET in patients with suspected malignancy. J Nucl Med. 2000;41:1411
  100. Gotway MB, Storto ML, Golden JA, et al. Incidental detection of thoracic sarcoidosis on whole-body (18)fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography. J Thorac Imaging. 2000;15:201–204
  101. Kobayashi A, Shinozaki T, Shinjyo Y, et al. FDG PET in the clinical evaluation of sarcoidosis with bone lesions. Ann Nucl Med. 2000;14:311–313
  102. Joe A, Hoegerle S, Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography. Clin Nucl Med. 2001;26:542
  103. Bakheet S, Powe J. Fluorine-18-fluorodeoxyglucose uptake in rheumatoid arthritis- associated lung disease in a patient with thyroid cancer. J Nucl Med. 1998;39:234–236
  104. Imran MB, Kubota K, Yoshioka S, et al. Sclerosing mediastinitis: Findings on fluorine-18 fluorodeoxyglucose position emission tomography. Clin Nucl Med. 1999;24:305–308
  105. Taylor IK, Hill AA, Hayes M, et al. Imaging allergen-invoked airway inflammation in atopic asthma with [18F]-fluorodeoxyglucose and positron emission tomography. Lancet. 1996;347:937–940
  106. Erasmus JJ, McAdams HP, Patz EF, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol. 1998;170:1369–1373
  107. Aoki J, Watanabe H, Shinozaki T, et al. FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr. 1999;23:603–608
  108. Zhuang H, Cunnane M, Ghesani N, et al. Chest tube insertion as a potential source of false-positive FDG-positron emission tomographic results. Clin Nucl Med. 2002;27:285–286
  109. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345–1348
  110. Zhuang H, Pourdehnad M, Lambridght E, et al. Dual time point FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–1417
  111. Gupta N, Gill H, Graeber G, et al. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998;114:1105–1111
  112. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301–1306
  113. 247P Nakamoto Y, Higashi T, Sakahara H, et al. Delayed FDG-PET scan for the differentiation between malignant and benign lesions. (abstr) J Nucl Med. 1999;40:
  114. 141P Kubota K, Yamaguchi K, Itoh M, et al. Whole body FDG-PET for tumor detection should be imaged at 2hr after injection. (abstr) J Nucl Med. 1999;40:
  115. (abstr) Herzog HR, Borner AR, Weckesser M, et al. Delayed scan time for FDG-PET in breast cancer. J Nucl Med. 1999;40:140P
  116. 76P Ishizu K, Nakamura S, Shiozaki T, et al. Increasing rate of FDG uptake from early to delayed PET images in lung tumors. (abstr) J Nucl Med. 2000;41:
  117. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glutt in human cancers. Cancer Res. 1996;56:1164–1167
  118. (abstr) Ponzo F, Zhuang HM, Liu FM, et al. Can the difference of the levels of glucose-6-phosphatase explain the mechanism of FDG-PET dual time point imaging?. Eur J Nucl Med. 2001;28:OS399
  119. Minn H, Kangas L, Knuutila V, et al. Determination of 2-fluoro-2-deoxy-d-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med. 1991;191:27–35
  120. Fischman AJ, Alpert NM. FDG-PET in oncology: There's more to it than looking at pictures. J Nucl Med. 1993;34:6–11
  121. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, l-leucine, l-methionine and FDG in cultured cancer cells. J Nucl Med. 1996;37:502–506
  122. Pauwels EKJ, Ribeiro MJ, Stoot J, et al. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317–322
  123. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose-metabolism: Useful parameter or oversimplification?. J Nucl Med. 1994;35:1308–1312
  124. Lodge MA, Lucas JD, Marsden PK, et al. A PET study of (18)FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22–30
  125. Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26:226–230
  126. Weber W, Young C, Abdel-Dayem HM, et al. Assessment of pulmonary lesions with F-18-fluorodeoxyglucose positron imaging using coincidence mode gama cameras. J Nucl Med. 1999;40:574–578
  127. (abstr) Hickeson M, Yun M, Zhuang HM, et al. Significance of corrected standardized uptake value by using the lesion size on CT scan for characterizing lung nodules on FDG-PET. J Nucl Med. 2001;42:275
  128. (abstr) Gupta NC, Tamim WZ, Bishop HA. Is there any incremental value of routine lymph node sampling using mediastinoscopy and/or thoracotomy or open biopsy for management of lung cancer patients following whole body PET?. J Nucl Med. 2000;41:298
  129. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumours. Br J Cancer. 1996;73:882–886
  130. Wallace WE, Gupta NC, Hubbs AF, et al. Cis-4-F-18 fluoro-l-proline PET imaging of pulmonary fibrosis in a rabbit model. J Nucl Med. 2002;43:413–420
  131. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction: Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis. 1983;128:833–838
  132. Betsuyaku T, Yoshioka A, Nishimura M, et al. Neutrophil elastase associated with alveolar macrophages from older volunteers. Am J Respir Crit Care Med. 1995;151:436–442
  133. Wallaert B, Gressier B, Marquette CH, et al. Inactivation of alpha-1-proteinase inhibitor by alveolar inflammatory cells from smoking patients with or without emphysema. Am Rev Respir Dis. 1993;147:1537–1543
  134. Miyauchi T, Wahl R. Regional 2-[18F]fluoro-2-deoxy-d-glucose uptake varies in normal lung. Eur J Nucl Med. 1996;23:517–523
  135. Newman SP, Wilding IR. Imaging techniques for assessing drug delivery in man. Pharm Sci Technol Today. 1999;2:181–189
  136. Dolovich MB. Measuring total and regional lung deposition using inhaled radiotracers. J Aerosol Med. 2001;14:S35–S44
  137. Yanai M, Hatazawa J, Ojima F, et al. Deposition and clearance of inhaled (18)FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J. 1998;11:1342–1348
  138. Berridge MS, Lee Z, Heald DL. Pulmonary distribution and kinetics of inhaled C-11 triamcinolone acetonide. J Nucl Med. 2000;41:1603–1611
  139. Fischman A, Babich J, Strauss H. A ticket to ride: Peptide radiopharmaceuticals. J Nucl Med. 1993;4:2253–2263
  140. Boerman O, Oyen W, Corstens F, et al. Liposomes for scintigraphic imaging: Optimization of in vivo behavior. Q J Nucl Med. 1998;42:271–279
  141. Rusckowski M, Paganelli G, Hnatowich DJ, et al. Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. J Nucl Med. 1996;37:1655–1662
  142. Samuel A, Paganelli G, Chiesa R, et al. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med. 1996;37:55–61
  143. Reuland P, Winker KH, Heuchert T, et al. Detection of infection in postoperative orthopedic patients with Tc-99m-labeled monoclonal antibodies against granulocytes. J Nucl Med. 1991;32:2209–2214
  144. Becker W, Goldenberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. In: Semin Nucl Med. 24:1994;p. 142–153
  145. Vinjamuri S, Hall AV, Solanki KK, et al. Comparison of Tc-99m infection imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet. 1996;347:233–235
  146. Yapar Z, Kibar M, Yapar AF, et al. The efficacy of technetium-99m ciprofloxacin (Infecton) imaging in suspected orthopaedic infection A comparison with sequential bone/gallium imaging. Eur J Nucl Med. 2001;28:822–830
  147. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. In: Proc Natl Acad Sci U S A. 97:2000;p. 9226–9233
  148. Heelan BT, Osman S, Blyth A, et al. Use of 2-F-18 fluoro-2-deoxyglucose as a potential agent in the prediction of graft rejection by positron emission tomography. Transplantation. 1998;66:1101–1103
  149. (abstr) Lehmann K, Behe M, Meller J, et al. F-18-FDG uptake in granulocytes: Basis of F-18-FDG scintigraphy for imaging infection. J Nucl Med. 2001;42:1384
  150. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–1980
  151. (abstr) Mamede M, Saga T, Ishimori T, et al. Differential uptake of F-18-FDG in experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of steroid pretreatment on tumor uptake. J Nucl Med. 2001;42:1172
  152. Chakrabarti R, Jung CY, Lee TP, et al. Changes in glucose-transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol. 1994;152:2660–2668
  153. Gamelli RL, Liu H, He LK, et al. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol. 1996;59:639–647
  154. Sorbara LR, Maldarelli F, Chamoun G, et al. Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression. J Virol. 1996;70:7275–7279
  155. Ahmed N, Kansara M, Berridge MV. Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 affinity for glucose is enhanced during the respiratory burst. Biochem J. 1997;327:369–375
  156. Tahara T, Ichiya Y, Kuwabara Y, et al. High [18]-fluorodeoxyglucose uptake in abdominal abscesses: A PET study. J Comput Assist Tomogr. 1989;5:829–831
  157. Meyer MA, Frey kA, Schwaiger M. Discordance between F-18 fluorodeoxyglucose uptake and contrast enhancement in a brain abscess. Clin Nucl Med. 1993;18:682–684
  158. Kaya Z, Kotzerke J, Keller F. FDG PET diagnosis of septic kidney in a renal transplant patient. Transpl Int. 1999;12:156
  159. Zimny M, Schroder W, Wolters S, et al. 18F-Fluorodeoxyglucose PET in ovarian carcinoma: Methodology and preliminary results. Nuklearmedizin. 1997;36:228–233
  160. Schroder W, Zimny M, Rudlowski C, et al. The role of F-18-fluoro-deoxyglucose positron emission tomography (F-18-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer. 1999;9:117–122
  161. Sugawara Y, Braun DK, Kison PV, et al. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: Preliminary results. Eur J Nucl Med. 1998;25:1238–1243
  162. Guhlmann A, Brecht-Krauss D, Sugar G, et al. Chronic osteomyelitis: Detection with FDG PET and correlation with histopathologic findings. Radiology. 1998;206:749–754
  163. Guhlmann A, Brecht-Krauss D, Suger G, et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med. 1998;39:2145–2152
  164. Zhuang H, Duarte PS, Pourdehand M, et al. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med. 2000;25:281–284
  165. Zhuang H, Duarte PS, Pourdehnad M, et al. The promising role of F-18-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med. 2001;42:44–48
  166. Hannah A, Scott AM, Akhurst T, et al. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis. J Nucl Med. 1996;37:1683–1685
  167. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med. 1995;20:434–435
  168. Tomas M, Tronco G, Karayalcin G, et al. FDG uptake in infectious mononucleosis. Clin Positron Imaging. 2000;39:176
  169. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259–264
  170. Yasuda S, Shohtsu A, Ide M, et al. Elevated F-18 FDG uptake in plasmocyte-rich chronic maxillary sinusitis. Clin Nucl Med. 1998;23:176–178
  171. Gysen M, Stroobants S, Mortelmans L. Proliferative myositis: A case of a pseudomalignant process. Clin Nucl Med. 1998;23:836–838
  172. Yasuda S, Shohtsu A, Ide M, et al. Diffuse FDG uptake in chronic thyroiditis. J Nucl Med. 1997;38:627
  173. Chang KJ, Zhuang HM, Alavi A. Detection of chronic recurrent lower extremity deep venous thrombosis on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med. 2000;25:838–839
  174. Bakheet S, Powe J, Kandil A, et al. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med. 2000;25:100–103
  175. Nunez RF, Yeung HWD, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nucl Med. 1999;24:281–282
  176. Ichiya Y, Kuwabara Y, Sasaki M, et al. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185–191
  177. (abstr) Zhuang H, Duarte P, Shnier D, et al. Exclusion of chronic osteomyelitis with FDG-PET. J Nucl Med. 1999;40:15|P
  178. Robiller FC, Stumpe KDM, Kossmann T, et al. Chronic osteomyelitis of the femur: Value of PET imaging. Eur Radiol. 2000;10:855–858
  179. Kalicke T, Schmitz A, Risse JH, et al. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: Results of histologically confirmed cases. Eur J Nucl Med. 2000;27:524–528
  180. Temmerman OPP, Heyligers IC, Hoekstra OS, et al. Detection of osteomyelitis using (18)FDG and positron emission tomography. J Arthroplasty. 2001;16:243–246
  181. Schmitz A, Risse JH, Grunwald F, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography findings in spondylodiscitis: Preliminary results. Eur Spine J. 2001;10:534–539
  182. Osman S, Danpure HJ. The use of 2-18F-fluoro-2-deoxy-d-glucose as a potential in vitro agent for labeling human granulocytes for clinical studies by positron emission tomography. Nucl Med Biol. 1992;19:183–190
  183. Forstrom LA, Mullan BP, Hung JC, et al. F-18-FDG labelling of human leukocytes. Nucl Med Commun. 2000;21:691–694
  184. Sugawara Y, Gutowski TD, Fisher SJ, et al. Uptake of positron emission tomography tracers in experimental bacterial infections: A comparative biodistribution study of radiolabeled FDG, thymidine, l-methionine, Ga-67-citrate, and I-125-HSA. Eur J Nucl Med. 1999;26:333–341
  185. Wahl RL, Henry CA, Ethier SP. Serum glucose: Effects on tumor and normal tissue accumulation of 2-F-18-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643–647
  186. Langen KJ, Braun U, Kops ER, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355–359
  187. Lindholm P, Minn H, Leskinenkallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study. J Nucl Med. 1993;34:1–6
  188. Diederichs CG, Staib L, Glatting G, et al. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030–1033
  189. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med. 2001;28:730–735
  190. (abstr) Zhuang HM, Loman JC, Cortes-Blanco A, et al. Hyperglycemia does not adversely affect FDG uptake by inflammatory and infectious lesions in FDG-PET imaging. J Nucl Med. 2000;41:1396
  191. Maitra SR, Wojnar MM, Lang CH. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock. 2000;13:379–385
  192. Weisdorf DJ, Craddock PR, Jacob HS. Granulocytes utilize different energy sources for movement and phagocytosis. Inflammation. 1982;6:245–256
  193. Lang CH, Bagby GJ, Dobrescu C, et al. Modulation of glucose metabolic response to endotoxin by granulocyte colony-stimulating factor. Am J Physiol. 1992;263:R1122–R1129
  194. Tetta C, Mariano F, Buades J, et al. Relevance of platelet-activating factor in inflammation and sepsis: Mechanisms and kinetics of removal in extracorporeal treatments. Am J Kidney Dis. 1997;30:S57–S65
  195. deKleijn E, Telgt D, Laan R. Schnitzler's syndrome presenting as fever of unknown origin (FUO): The role of cytokines in its systemic features. Neth J Med. 1997;51:140–142
  196. Chang HR, Bistrian B. The role of cytokines in the catabolic consequences of infection and injury. JPEN J Parenter Enteral Nutr. 1998;22:156–166
  197. Yue T, Rabinovici R, Feuerstein G. Platelet-activating factor (PAF) — A putative mediator in inflammatory tissue injury. Adv Exp Med Biol. 1991;314:223–233
  198. Martin T, Losa JE, Garciasalgado MJ, et al. The role of platelet-activating factor (PAF) in interstitial pulmonary disease. J Investig Allergol Clin Immunol. 1994;4:149–157
  199. Lang CH, Dobrescu C, Hargrove DM, et al. Platelet-activating factor-induced increases in glucose kinetics. Am J Physiol. 1988;254:E193–E200
  200. Ottlakan A. Role of platelet-activating factor in glucose uptake and utilization of different tissuess. Eur Surg Res. 1998;30:393–402
  201. Shearer JD, Amaral JF, Caldwell MD. Glucose metabolism of injured skeletal muscle: The contribution of inflammatory cells. Circ Shock. 1988;25:131–138
  202. Chisholm PM, Danpure HJ, Healey G, et al. Cell damage resulting from the labeling of rat lymphocytes and Hela S3 cells with In-111 oxine. J Nucl Med. 1979;20:1308–1311
  203. (abstr) Kuyama J, McCormack A, George AJT, et al. Indium-111 labelled lymphocytes: Isotope distribution and cell division. Eur J Nucl Med. 1997;24:488–496
  204. (abstr) Fischman AJ, Carter EA, Coco-Graham WA, et al. Comparison of a Tc-99m chemotactic peptide with (18)FDG for imaging infection and sterile inflammation in rabbits. J Nucl Med. 1999;40:894
  205. Peters AM. The use of nuclear medicine in infections. Br J Radiol. 1998;71:252–261
  206. Scharko AM, Perlman SB, Hinds PW, et al. Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. In: Proc Natl Acad Sci U S A. 93:1996;p. 6425–6430
  207. Wallace M, Pyzalski R, Horejsh D, et al. Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology. 2000;274:255–261
  208. O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–1583
  209. Peter AM. Nuclear medicine imaging in fever of unknown origin. Q J Nucl Med. 1999;43:61–73
  210. De Winter F, Petrovic M, Van de Wiele C, et al. Imaging of giant cell arteritis: Evidence of splenic involvement using FDG positron emission tomography. Clin Nucl Med. 2000;25:633–634
  211. Turlakow A, Yeung HWD, Pui J, et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med. 2001;161:1003–1007
  212. (abstr) Maes A, Blockmans D, Stroobants S, et al. Diagnosis of systemic vasculitis using positron emission tomography. J Nucl Med. 1998;39:1170
  213. Blockmans D, Maes A, Stroobants S, et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology. 1999;38:444–447
  214. Hara M, Goodman PC, Leder RA. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr. 1999;23:16–18
  215. Derdelinckx I, Maes A, Bogaert J, et al. Positron emission tomography scan in the diagnosis and follow-up of aortitis of the thoracic aorta. Acta Cardiol. 2000;55:193–195
  216. Marik PE, Andrews L, Maini B. The incidence of deep venous thrombosis in ICU patients. Chest. 1997;111:661–664
  217. Stein PD, Afzal A, Henry JW, et al. Fever in acute pulmonary embolism. Chest. 2000;117:39–42
  218. (abstr) Dreyer M, Borgwardt L, Reichnitzer C, et al. The role of whole body FDG-PET in pediatric patients with vever of unknown origin. J Nucl Med. 2001;42:142
  219. Mortelmans LA, De Caestecker J, Maes A, et al. Diagnostic role of whole body FDG PET in patients with fever of unknown origin (FUO). J Nucl Med. 1999;40:899
  220. Meller J, Altenvoerde G, Lehmann K, et al. Fever of unknown origin: Prospective comparison of 18 FDG imaging with a double head coincidence camera (DHCC) and Ga-67 citrate SPECT. Eur J Nucl Med. 2001;28:OS387
  221. Blockmans D, Knockaert D, Maes A, et al. Clinical value of F-18 fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis. 2001;32:191–196
  222. Muller-Quernheim J. Sarcoidosis: Clinical manifestations, staging and therapy (part II). Respir Med. 1998;92:140–149
  223. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. In: Semin Nucl Med. 32:2002;p. 47–59
  224. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696–703
  225. Gungor T, Engel-Bicik I, Eich G, et al. Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-d-glucose in children with chronic granulomatous disease. Arch Dis Child. 2001;85:341–345
  226. Engel-Bicik I, Seger R, Eich G, et al. Diagnostic and therapeutic impact of whole body PET with FDG in immunodeficient children and fever of unknown origin. Eur J Nucl Med. 1999;26:OS58
  227. Schmitz A, Kalicke T, Willkomm P, et al. Use of fluorine-18 fluoro-2-deoxy-d-glucose positron emission tomography in assessing the process of tuberculous spondylitis. J Spinal Disord. 2000;13:541–544
  228. Franzius C, Biermann M, Hulskamp G, et al. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clin Nucl Med. 2001;26:232–233
  229. Reuter S, Schirrmeister H, Kratzer W, et al. Pericystic metabolic activity in alveolar echinococcosis: Assessment and follow-up by positron emission tomography. Clin Infect Dis. 1999;29:1157–1163
  230. Falaschi F, Battolla L, Mascalchi M, et al. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am J Roentgenol. 1996;166:963–968
  231. Benard F, Sterman D, Smith R, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–722
  232. Schneider DB, Clary-Macy C, Challa S, et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120:128–133
  233. Zubeldia J, Abou-Zied M, Nabi H. Evaluation of patients with known mesothelioma with fluorodeoxyglucose and PET. Comparison with computed tomography. Clin Positron Imaging. 2000;3:165
  234. Belhocine T, Daenen F, Duysinx B, et al. Typical appearance of mesothelioma on an F-18 FDG positron emission tomograph. Clin Nucl Med. 2000;25:636
  235. Benard F, Sterman D, Smith R, et al. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 1999;40:1241–1245
  236. Naruke T, Goya T, Tsuchiya R. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96:440–447
  237. Erasmus J, McAdams H, Rossi S, et al. FDG-PET of pleural effusion in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000;175:245–249
  238. Gupta N, Rogers J, Graeber G: Clinical role of PET-FDG imaging in patients with lung cancer and suspected malignant pleural effusion. Chest (in press)
  239. Bury T, Paulus P, Dowlati A, et al. Evaluation of pleural diseases with FDG-PET imaging: Preliminary report. Thorax. 1997;52:187–189
  240. Buchmann I, Guhlmann C, Elsner K, et al. F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes. Nuklearmedizin. 1999;38:319–322
  241. Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases: A pilot study. Eur J Cardiothorac Surg. 2000;17:377–383
  242. Hickeson M, Yun M, Matthies A, et al: Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging (in press)

PII: S0001-2998(02)80020-4

doi: 10.1053/snuc.2002.127291

Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 293-321 , October 2002

Article Tools